Vident Advisory, LLC Tg Therapeutics, Inc. Transaction History
Vident Advisory, LLC
- $10.5 Trillion
- Q3 2025
A detailed history of Vident Advisory, LLC transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Vident Advisory, LLC holds 11,603 shares of TGTX stock, worth $359,693. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,603
Previous 13,874
16.37%
Holding current value
$359,693
Previous $499 Million
16.06%
% of portfolio
0.0%
Previous 0.01%
Shares
5 transactions
Others Institutions Holding TGTX
# of Institutions
394Shares Held
90.5MCall Options Held
1.77MPut Options Held
1.9M-
Vanguard Group Inc Valley Forge, PA15.5MShares$481 Million0.01% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$353 Million0.0% of portfolio
-
State Street Corp Boston, MA8.1MShares$251 Million0.01% of portfolio
-
Clearbridge Investments, LLC New York, NY4.64MShares$144 Million0.13% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT3.84MShares$119 Million8.45% of portfolio
About TG THERAPEUTICS, INC.
- Ticker TGTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 145,274,000
- Market Cap $4.5B
- Description
- TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...